LEAD ANTI-CANCER CANDIDATE

Theryte is currently testing the efficacy of its lead candidate, THR-53, in cancer models, and expects to complete a package of early-stage pharmacology and safety trials.  The Company is interested in talking to parties who wish to license or co-develop this potential blockbuster.

ANTICANCER DRUG TARGET

In order to develop new chemical entities against its "breakthrough" targets for the general treatment of cancer, Theryte now seeks a partnership with a company engaged in assay development, target screening and medicinal chemistry.

BIOMARKERS

A strategic partner and investor, Randox Laboratories Ltd., is responsible for commercialising Theryte’s theranostic tests, under exclusive licence, on proteomic chips with a view to selling specific theranostic biomarker kits.